Vitalis, LLC products

ER (extended-release) niacin currently has six FDA approved indications and has been prescribed to millions of patients in the U.S. alone (Jackevicius et al.). However, a well-known side effect of treating with ER niacin is Niacin Flush (Mills et al.). The Niacin Flush is a historical term for the medical syndrome of the “skin on fire” experience of these patients. Niacin Flush can be felt and seen just hours after ingesting the ER niacin (Mills et al.) and can be incredibly painful. Patients who experience Niacin Flush skip doses of or discontinue ER niacin (Rhodes et al.), a potentially life-saving medication.

Aspirin is one of the oldest, most complex drugs in medicine, with many different indications and applications. It has unique pharmacokinetic properties where its metabolites effect aspirin itself, depending on the rates of metabolism in different parts of the body.

VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for RRMS with fewer side effects and other clinical benefits for these patients.

VTS-K is being developed with the aim of helping: to reduce the use and dosage of opioid medications for post-op pain management, and to enable patients to get out of bed more quickly.